OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 02, 2009
How to implement a risk-based approach to eliminate viruses using orthogonal technologies.
October 01, 2009
The industry and government must collaborate to develop robust technologies and quicker, more flexible manufacturing approaches for vaccine development.
New technologies such as virus-like particles are promising weapons in the battle against pandemic influenza.
Membrane-based TFF technology can ease scale-up and provide a higher recovery percentage compared to conventional purification methods.
It is now possible to combine antigens with specific adjuvant systems to create more effective vaccines.
Needle-free vaccine delivery platforms can solve the problems of stockpiling, cold-chain management, and pandemic preparedness.